Skip to main content
رجوع
Watch Compare

Jin Medical International Ltd.

جودة البيانات: 100%
ZJYL
NASDAQ Manufacturing Measuring & Analyzing Instruments
KWD 2.13
▼ KWD 0.18 (-7.79%)
6 months return
—
Momentum
Neutral
1Y earnings growth
-67.59%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-11.98%
Earnings (1Y)-67.59%
FCF Growth (3Y)N/A

الجودة

Return on Equity
4.40%
أعلى من متوسط القطاع (-54.49%)
ROIC1.32%
Net Margin5.76%
Op. Margin2.94%

الأمان

Debt / Equity
0.56
أعلى من متوسط القطاع (0.30)
Current Ratio2.11
Interest CoverageN/A

التقييم

PE (TTM)
15.18
أعلى من متوسط القطاع (-1.50)
P/B Ratio0.65
EV/EBITDA39.70
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Earnings declined -67.59% over the past year
ROE of 4.40% is below average
Negative free cash flow of -3.73 M
Capital intensive — 32.05% of revenue goes to capex
ROIC of 1.32% — low return on invested capital

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

Growth

Rev 5Y: N/A · Earnings 1Y: -67.59%
Revenue Growth (1Y) -11.98% Revenue Growth (3Y) 2.16%
Earnings Growth (1Y) -67.59% Earnings Growth (3Y) -35.67%
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: 4.40% · Net Margin: 5.76%
Revenue (TTM) 20.69 M Net Income (TTM) 1.19 M
ROE 4.40% ROA 2.66%
Gross Margin 29.22% Operating Margin 2.94%
Net Margin 5.76% Free Cash Flow (TTM) -3.73 M
ROIC 1.32% FCF Growth (3Y) N/A

Safety

D/E: 0.56 · Current: 2.11
Debt / Equity 0.56 Current Ratio 2.11
Interest Coverage N/A Asset Turnover 0.46
Working Capital 23.04 M Tangible Book Value 26.82 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: 15.18 · EV/EBITDA: 39.70
P/E Ratio 15.18 Forward P/E N/A
P/B Ratio 0.65 P/S Ratio 0.87
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 39.70 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -20.61%
Market Cap 18.08 M Enterprise Value 33.81 M

Per Share

EPS: 0.01 · FCF/Share: -0.48
EPS (Diluted TTM) 0.01 Revenue / Share 2.64
FCF / Share -0.48 OCF / Share 0.37
EPS CAGR (1Y) -50.00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: -312.79% · CapEx/Rev: 32.05%
CapEx / Revenue 32.05% FCF Conversion -312.79%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 20.69 M 23.50 M 19.82 M
Net Income 1.19 M 3.68 M 2.88 M
EPS (Diluted) 0.01 0.02 0.02
Gross Profit 6.04 M 9.50 M 6.78 M
Operating Income 608,182.0 3.64 M 2.87 M
EBITDA — — —
R&D Expenses 1.56 M 1.50 M 1.54 M
SG&A Expenses — — —
D&A 243,403.0 237,823.0 225,902.0
Interest Expense — — 182,682.0
Income Tax 214,572.0 763,879.0 343,707.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 53.37 M 45.80 M 32.90 M
Total Liabilities 23.80 M 17.25 M 8.92 M
Shareholders' Equity 29.64 M 28.82 M 23.98 M
Total Debt 18.84 M 11.32 M —
Cash & Equivalents — — —
Current Assets 44.14 M 42.82 M 31.12 M
Current Liabilities 23.80 M 17.15 M 8.92 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E 15.2 -1.5
P/B 0.7 1.6
ROE % 4.4 -54.5
Net Margin % 5.8 -41.5
Rev Growth 5Y % — 1.8
D/E 0.6 0.3